Engaging Loved ones in Recovery Processes to Enhance Recovery Capital and Outcomes (R61/R33 Clinical Trial Optional)
ID: 356999Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356999

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-024.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Engaging Loved Ones in Recovery Processes to Enhance Recovery Capital and Outcomes" (RFA-DA-26-024), aimed at addressing the critical research gap regarding the involvement of family and support persons in the recovery of individuals with substance use disorders (SUDs). This initiative encourages phased R61/R33 studies that focus on developing interventions to improve the well-being of support persons and enhance engagement strategies that consider family dynamics. The program emphasizes the importance of a recovery capital framework to evaluate both individual and familial outcomes, with approximately $3 million allocated for four anticipated awards. Interested applicants should prepare to submit their proposals by the deadline of February 27, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-26-024.html
    The National Institutes of Health (NIH) is issuing a funding opportunity titled "Engaging Loved Ones in Recovery Processes to Enhance Recovery Capital and Outcomes" (RFA-DA-26-024), aimed at addressing the research gap regarding the role of family and support persons in the recovery of individuals with substance use disorders (SUDs). This funding opportunity encourages phased R61/R33 studies focusing on the intricate relationships between those with SUDs and their loved ones. High-priority areas include developing interventions for the well-being of support persons, enhancing knowledge of effective SUD interventions, and testing engagement strategies that involve family dynamics. The program seeks projects that utilize a recovery capital framework to evaluate individual and familial outcomes, incorporate diverse perspectives, and ensure stakeholder engagement. Funding of approximately $3 million is allocated for four anticipated awards, supporting innovative research designed to improve recovery pathways. Applications will be subject to a rigorous review process and should include detailed plans, including a required Plan for Enhancing Diverse Perspectives (PEDP). Key dates include opening on January 27, 2025, and application submission deadlines for the project phases. The initiative reflects a commitment to understanding the critical role of familial support in combating SUDs and enhancing recovery efforts.
    Similar Opportunities
    Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)," aimed at advancing translational research in the field of substance use. This initiative encourages researchers to engage in a two-phase research process, starting with an R61 planning phase lasting up to two years, followed by an R33 phase for larger studies that may extend up to four years, contingent upon meeting specific milestones. The program emphasizes the importance of community stakeholder engagement and mandates a Plan for Enhancing Diverse Perspectives (PEDP) in all proposals to ensure inclusivity in research development. Interested applicants can find more information and submit their proposals by December 14, 2026, and should direct inquiries to grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)" aimed at encouraging clinical research to identify and validate novel targets for non-invasive brain stimulation (NIBS) related to substance use disorders (SUD). This initiative seeks exploratory and developmental studies that may involve significant risks but have the potential to lead to breakthroughs in understanding the neurobiological and behavioral responses associated with SUD treatment. The funding opportunity includes a budget cap of $600,000 for the R61 phase, with a total of up to $1.5 million available across multiple awards, and requires applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP). Interested applicants should note that the application period opens on December 16, 2023, and closes on August 14, 2026; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis" (RFA-DA-25-078), aimed at supporting research that transforms addiction treatment and care to combat the ongoing overdose crisis. This initiative encourages phased applications (R61/R33), where the R61 phase focuses on exploratory activities without the need for existing pilot data, while the R33 phase seeks to implement larger studies based on successful R61 milestones, emphasizing stigma-free and patient-centered approaches. With up to $10 million allocated for FY2026 and a maximum award period of six years, applicants must include a Plan for Enhancing Diverse Perspectives (PEDP) to ensure inclusivity, and applications are to be submitted through Grants.gov by the closing date of March 20, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for exploratory clinical neuroscience research focused on substance use disorders (SUD) through the R61/R33 phased innovation award mechanism. This funding opportunity aims to support clinical research proposals that investigate the neurobiological mechanisms underlying SUD, allowing for up to five years of funding, with the R61 phase dedicated to initial concept testing and the R33 phase contingent upon achieving specific milestones. The initiative is crucial for advancing understanding of substance abuse impacts in the U.S., encouraging innovative research on topics such as neural circuitry and cognitive factors influencing addiction. Interested applicants, including various educational and nonprofit institutions, can find more details and submit applications by the closing date of May 7, 2026, with no cost-sharing requirement. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html.
    HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis," aimed at supporting research that translates findings into practical solutions for addressing the overdose crisis. This initiative encourages applications from a diverse range of organizations, including educational institutions and nonprofits, with a focus on developing stigma-free, patient-centered systems for addiction recovery and improving the quality of addiction treatment services. The NIH plans to commit approximately $10 million to fund grants, with an expected award ceiling of $750,000 for up to 12 awards, and applications will be accepted starting February 20, 2025, with a closing date of March 20, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-077.html.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)" aimed at advancing clinical research in the field of substance use disorders (SUD). The primary objective is to identify and validate novel targets for non-invasive brain stimulation (NIBS) and to explore the neurobiological, cognitive, and behavioral responses associated with NIBS that may lead to improved clinical outcomes such as reduced cravings or drug use. This initiative is crucial for enhancing understanding and treatment options for SUD through innovative research methodologies. Funding of up to $1.5 million is available for selected projects over a maximum project period of five years, with applications due by August 14, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application instructions available at the provided link.
    Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders" (R21/R33), aimed at supporting research projects that explore the genetic underpinnings of substance use disorders. This initiative encourages researchers to utilize innovative methodologies, such as CRISPR technologies, to validate addiction-relevant genes and characterize their roles in living organisms or human organoid systems, thereby enhancing the understanding of neurobiological mechanisms associated with addiction. The funding allows for up to $125,000 per year for the R21 phase over two years and up to $250,000 annually for the R33 phase over three years, with applications due by 5:00 PM local time on February 3, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-267.html.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications that support a diverse range of preclinical and clinical projects, with the goal of advancing medication studies toward FDA approval, emphasizing the importance of innovative approaches to drug misuse and addiction treatment. Eligible applicants include a variety of institutions, such as higher education entities and community organizations, with funding available up to $5 million per year for projects lasting up to three years. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by August 11, 2025.